.Pirada Suphaphiphat Allen

Dr. .Pirada Suphaphiphat Allen


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2024 in npj Vaccines
Verified
Journal Article
Open access
PDF file
THTeresa Hauguel
Teresa Hauguel
ASAmy Sharma
Amy Sharma
EMEmily Mastrocola
Emily Mastrocola
SLSusan Lowry
Susan Lowry
MMMohan S. Maddur
Mohan S. Maddur
.A.Pirada Suphaphiphat Allen
.Pirada Suphaphiphat Allen
Seasonal epidemics of influenza viruses are responsible for a significant global public health burden. Vaccination remains the most effective way to prevent infection; however, due to the persistence of antigenic drift, vaccines must be updated annually. The selection of vaccine strains occurs months in advance of the influenza season to allow adequate time for production in eggs. RNA vaccines offer the potential to accelerate production and improve efficacy of influenza vaccines. We leveraged the nucleoside-modified RNA (modRNA) platform technology and lipid nanoparticle formulation process of the COVID-19 mRNA vaccine (BNT162b2; Comirnaty®) to create modRNA vaccines encoding hemagglutinin (HA) (modRNA-HA) for seasonal human influenza strains and evaluated their preclinical immunogenicity and toxicity. In mice, a monovalent modRNA vaccine encoding an H1 HA demonstrated robust antibody responses, HA-specific Th1-type CD4+ T cell responses, and HA-specific CD8+ T cell responses. In rhesus and cynomolgus macaques, the vaccine exhibited durable functional antibody responses and HA-specific IFN-γ+ CD4+ T cell responses. Immunization of mice with monovalent, trivalent, and quadrivalent modRNA-HA vaccines generated functional antibody responses targeting the seasonal influenza virus(es) encoded in the vaccines that were greater than, or similar to, those of a licensed quadrivalent influenza vaccine. Monovalent and quadrivalent modRNA-HA vaccines were well-tolerated by Wistar Han rats, with no evidence of systemic toxicity. These nonclinical immunogenicity and safety data support further evaluation of the modRNA-HA vaccines in clinical studies.

3 April 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
Angela R. BrancheAngela R. Branche
Angela R. Branche
MMMark J. Mulligan
Mark J. Mulligan
AMAlok Maniar
Alok Maniar
OPOrlando Puente
Orlando Puente
Islamiat OladipupoIslamiat Oladipupo
Islamiat Oladipupo
KLKelly Lindert
Kelly Lindert
Background/Objectives: Circulating influenza strains antigenically differing from vaccine antigens increase disease burden by decreasing vaccine efficacy. Nucleoside-modified mRNA (modRNA) influenza vaccines may facilitate rapid production allowing later antigen selection and improved antigenic similarity compared to circulating strains. We studied different influenza modRNA vaccine (IRV) formulations and dose levels. Methods: This phase 1/2 randomized study evaluated IRV safety/tolerability and immunogenicity in healthy 18- through 85-year-olds. Based on safety and immunogenicity for different IRV doses, schedules, and valencies versus the quadrivalent influenza vaccine (QIV; Fluzone High-Dose Quadrivalent, Sanofi Pasteur) in phase 1 (65–85-year-olds), quadrivalent IRV (qIRV) was further evaluated in 65- through 85-year-olds and 18- through 64-year-olds in phase 2, leading to phase 3 dose selection. Results: Phase 1 (65–85-year-olds) safety/tolerability and immunogenicity findings supported qIRV 30-µg and 60-µg phase 2 assessment (18–85-year-olds, N = 610). qIRV was well tolerated. Injection site pain was the most frequently reported local reaction. Reactogenicity event incidences ≤ 7 days postvaccination for qIRV were generally higher versus QIV, observed more frequently in 18- through 64-year-olds than 65- through 85-year-olds, and showed dose-related trends (60 μg > 30 μg). qIRV and QIV adverse event profiles in 65- through 85-year-olds were similar. There were higher postvaccination hemagglutination inhibition assay geometric mean titers and fold rises and seroconversion rates observed with qIRV versus QIV for A strains, with no consistent pattern for B strains. Cell-mediated immune responses to qIRV by Day 7 showed overall higher T-cell responses against all strains versus QIV. Antibody and cell-mediated immune responses showed comparable trends across qIRV doses in 18- through 85-year-olds; a dose-related pattern was observed in 65- through 85-year-olds (60 μg > 30 μg). Conclusions: Phase 3 investigations of qIRV 60 µg in older adults and qIRV 30 µg in younger adults are warranted (ClinicalTrials.gov Identifier: NCT05052697).

29 November 2025 in npj Vaccines
Verified
Journal Article
Open access
PDF file
MHMasato Hatta
Masato Hatta
NBNicole Brock
Nicole Brock
THTeresa Hauguel
Teresa Hauguel
CFChenchen Feng
Chenchen Feng
YHYing Huang
Ying Huang
BZBin Zhou
Bin Zhou
The global spread of highly pathogenic avian influenza A(H5N1) viruses poses a serious pandemic threat. While sustained human-to-human transmission has not occurred, widespread circulation in birds, increased detection in mammals, and occasional human spillovers underscore the need for safe and effective vaccines. We evaluated an H5 mRNA vaccine candidate in ferrets using recent clade 2.3.4.4b A(H5N1) human isolates. Vaccination elicited strong neutralizing antibodies, conferred robust protection against lethal challenge, and significantly reduced viral titers. In a direct contact transmission model, mRNA vaccination decreased virus shedding in inoculated ferrets and reduced onward transmission; it also protected vaccinated contact ferrets from infection following exposure to virus-shedding, unvaccinated ferrets. Additionally, sera from vaccinated animals cross-neutralized clade 2.3.2.1e human viruses to varying degrees, depending on the strain. These findings demonstrate that H5 mRNA vaccination not only protects against disease but also reduces transmission, supporting its potential as a key tool for pandemic preparedness.

15 April 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
RDRucha Dadhe
Rucha Dadhe
JGJuleen Gayed
Juleen Gayed
MIMuneeb Iqbal
Muneeb Iqbal
RSRohit Solan
Rohit Solan
HWHan Wu
Han Wu
KLKelly Lindert
Kelly Lindert
Background/Objectives: This study evaluated the Omicron LP.8.1 variant-adapted BNT162b2 mRNA vaccine (LP.8.1-adapted BNT162b2). Methods: This analysis is part of an ongoing phase 3 open-label study evaluating the immunogenicity, safety, and tolerability of LP.8.1-adapted BNT162b2. Reported here are descriptive 2-week post-vaccination results in 18–64 -year-olds at high risk of severe COVID-19 and in ≥65-year-olds who received the Omicron KP.2-adapted COVID-19 vaccine ≥ 6 months previously. Primary immunogenicity endpoints included neutralizing antibody geometric mean titers (GMTs) against LP.8.1 and KP.2 at 2 weeks after vaccination and geometric mean fold rises from baseline to 2 weeks after vaccination. Results were compared with a historical control group of adults who received KP.2-adapted BNT162b2 in a previous study. Tolerability and safety were also assessed. Results: Overall, 104 participants received LP.8.1-adapted BNT162b2 (18–64-year-olds, n = 51; ≥65-year-olds, n = 53). Baseline neutralizing GMTs were higher in LP.8.1-adapted BNT162b2 recipients than in the historical control group of KP.2-adapted BNT162b2 recipients against both sublineages (248 vs. 157 against LP.8.1; 372 vs. 187 against KP.2). Serum-neutralizing LP.8.1 and KP.2 GMTs increased 2 weeks after vaccination with LP.8.1-adapted BNT162b2 (1752 against LP.8.1; 2104 against KP.2) and historical control groups (1555 and 2395, respectively), and across both age groups. Reactogenicity events with LP.8.1-adapted BNT162b2 were generally mild or moderate and occurred at generally similar frequencies in both age groups. Adverse events were reported in 4.8% of participants (all in 18–64-year-olds); no serious adverse events were reported. Conclusions: After 2 weeks of follow-up, and in a small sample size, LP.8.1-adapted BNT162b2 was immunogenic in ≥65-year-olds and ≥18-year-olds at high risk of severe COVID-19. The safety and tolerability profile for LP.8.1-adapted BNT162b2 was consistent with the current US prescribing information for BNT162b2 and that of other variant-adapted BNT162b2 vaccines (Clinicaltrials.gov Identifier: NCT07069309, registered 16 July 2025).

5 August 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
YPYanely Pineiro Puebla
Yanely Pineiro Puebla
HNHelen Nicholls
Helen Nicholls
DFDavid Fitz-Patrick
David Fitz-Patrick
LHLucy Horton
Lucy Horton
MGMatthew Wiestaw Gawel
Matthew Wiestaw Gawel
KLKelly Lindert
Kelly Lindert
Background/Objectives: Vaccination remains an important means of protection against influenza and COVID-19. Administering influenza and COVID-19 vaccines as a combined formulation may be advantageous. Methods: This phase 3, randomized study evaluated an investigational combination nucleoside-modified messenger RNA (modRNA) vaccine formulated with monovalent XBB.1.5-adapted BNT162b2 vaccine (BNT162b2) and an investigational influenza modRNA vaccine (hereafter investigational combination modRNA vaccine); we report safety, tolerability, and immunogenicity of the investigational combination modRNA vaccine in healthy 18- to 64-year-olds in two cohorts (2 and 3). Results: In Cohort 2, 3127 participants received the investigational combination modRNA vaccine and 1563 received the concomitant licensed quadrivalent influenza vaccine (QIV) with BNT162b2. In Cohort 3, 1189 participants received the investigational combination modRNA vaccine, 605 received QIV, 607 received the investigational influenza modRNA vaccine, and 1191 received BNT162b2. Prespecified noninferiority criteria of the geometric mean ratio of strain-specific hemagglutination inhibition (HAI) or SARS-CoV-2 Omicron XBB.1.5 neutralizing titers or differences in percentages of participants achieving HAI sero-conversion or Omicron XBB.1.5 seroresponse for investigational combination modRNA vaccine to concomitant QIV and BNT162b2 (or to QIV and BNT162b2 each administered alone in Cohort 3) were met for influenza A and SARS-CoV-2 Omicron XBB.1.5 strains but not for the influenza B strain. The investigational combination modRNA vaccine was well tolerated with an acceptable safety profile. Conclusions: The single-dose investigational combination influenza plus COVID-19 modRNA vaccine elicited robust immune responses against influenza A and SARS-CoV-2 with acceptable safety. Further work is required to optimize influenza B responses. The modRNA platform offers promise and potential advantages for vaccine development. ClinicalTrials.gov Identifier: NCT06178991 (approval date: 20 December 2023).